These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19209708)

  • 21. 3D QSAR and docking study of flavone derivatives as potent inhibitors of influenza H1N1 virus neuraminidase.
    Gao L; Zu M; Wu S; Liu AL; Du GH
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5964-70. PubMed ID: 21843936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel binding patterns between ganoderic acids and neuraminidase: Insights from docking, molecular dynamics and MM/PBSA studies.
    Yang Z; Wu F; Yuan X; Zhang L; Zhang S
    J Mol Graph Model; 2016 Apr; 65():27-34. PubMed ID: 26905206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 2. Computational titration and pH effects in molecular models of neuraminidase-inhibitor complexes.
    Fornabaio M; Cozzini P; Mozzarelli A; Abraham DJ; Kellogg GE
    J Med Chem; 2003 Oct; 46(21):4487-500. PubMed ID: 14521411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docking and 3D QSAR study of thiourea analogs as potent inhibitors of influenza virus neuraminidase.
    Sun J; Cai S; Mei H; Li J; Yan N; Wang Y
    J Mol Model; 2010 Dec; 16(12):1809-18. PubMed ID: 20213331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1.
    Malaisree M; Rungrotmongkol T; Decha P; Intharathep P; Aruksakunwong O; Hannongbua S
    Proteins; 2008 Jun; 71(4):1908-18. PubMed ID: 18175324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Creation of a generalized model prediction of inhibition of neuraminidase of influenza virus of various strains].
    Mikurova AV; Skvortsov VS
    Biomed Khim; 2018 Jun; 64(3):247-252. PubMed ID: 29964260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
    Foffi G; Pastore A; Piazza F; Temussi PA
    Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the absolute affinity of neuraminidase inhibitor using steered molecular dynamics simulations.
    Tam NM; Nguyen MT; Ngo ST
    J Mol Graph Model; 2017 Oct; 77():137-142. PubMed ID: 28854402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. QSAR modeling and molecular interaction analysis of natural compounds as potent neuraminidase inhibitors.
    Sun J; Mei H
    Mol Biosyst; 2016 Apr; 12(5):1667-75. PubMed ID: 27008437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuraminidase inhibitor R-125489--a promising drug for treating influenza virus: steered molecular dynamics approach.
    Mai BK; Li MS
    Biochem Biophys Res Commun; 2011 Jul; 410(3):688-91. PubMed ID: 21693105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
    Pan P; Li L; Li Y; Li D; Hou T
    Antiviral Res; 2013 Nov; 100(2):356-64. PubMed ID: 24055835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atypical group 1 neuraminidase pH1N1-N1 bound to a group 1 inhibitor.
    Wu Y; Vavricka CJ; Wu Y; Li Q; Rudrawar S; Thomson RJ; von Itzstein M; Gao GF; Qi J
    Protein Cell; 2015 Oct; 6(10):771-3. PubMed ID: 26334400
    [No Abstract]   [Full Text] [Related]  

  • 33. Analysis of inhibitor binding in influenza virus neuraminidase.
    Smith BJ; Colman PM; Von Itzstein M; Danylec B; Varghese JN
    Protein Sci; 2001 Apr; 10(4):689-96. PubMed ID: 11274459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacophore model of influenza neuraminidase inhibitors--a systematic review.
    Gong JZ; Liu Y; Xu WF
    Pharmazie; 2009 Oct; 64(10):627-32. PubMed ID: 19947162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The binding properties of the H5N1 influenza virus neuraminidase as inferred from molecular modeling.
    Raab M; Tvaroška I
    J Mol Model; 2011 Jun; 17(6):1445-56. PubMed ID: 20853123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation.
    Malaisree M; Rungrotmongkol T; Nunthaboot N; Aruksakunwong O; Intharathep P; Decha P; Sompornpisut P; Hannongbua S
    Amino Acids; 2009 Oct; 37(4):725-32. PubMed ID: 19002747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of neuraminidase-substrate recognition using molecular dynamics and free energy calculations.
    Masukawa KM; Kollman PA; Kuntz ID
    J Med Chem; 2003 Dec; 46(26):5628-37. PubMed ID: 14667217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of mutation on the drug binding affinity of Neuraminidase: case study of Capsaicin using steered molecular dynamics simulation.
    Sedighpour D; Taghizadeh H
    J Mol Model; 2022 Jan; 28(2):36. PubMed ID: 35024968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A first-order system least-squares finite element method for the Poisson-Boltzmann equation.
    Bond SD; Chaudhry JH; Cyr EC; Olson LN
    J Comput Chem; 2010 Jun; 31(8):1625-35. PubMed ID: 19908291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A stabilized finite volume element method for solving Poisson-Nernst-Planck equations.
    Li J; Ying J
    Int J Numer Method Biomed Eng; 2022 Jan; 38(1):e3543. PubMed ID: 34716987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.